bicalutamide has been researched along with Metastase in 31 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (16.13) | 18.2507 |
| 2000's | 7 (22.58) | 29.6817 |
| 2010's | 16 (51.61) | 24.3611 |
| 2020's | 3 (9.68) | 2.80 |
| Authors | Studies |
|---|---|
| Cao, J; Du, X; Liang, Z; Lin, Q; Liu, H; Shen, Y; Shi, J; Tian, L; Yang, X; Zhang, J; Zhang, R | 1 |
| Boers, J; Boersma, HH; de Vries, EFJ; Dorbritz, C; Glaudemans, AWJM; Hospers, GAP; Rikhof, B; Schröder, CP; Venema, CM | 1 |
| Attard, G; Bahary, JP; Dabbas, B; Das, R; Davicioni, E; Dicker, AP; Dignam, JJ; Efstathiou, JA; Feng, FY; Hall, WA; Huang, HC; Liu, YS; Lukka, HR; Margrave, J; Nguyen, PL; Pisansky, TM; Pollack, A; Pugh, SL; Sandler, HM; Shah, AB; Shipley, WU; Simko, JP; Spratt, DE; Sweeney, C; Thompson, DJS; Todorovic, T; Tran, PT; Zhao, SG | 1 |
| Agbarya, A; Bar-Sela, G; Charas, T; Hijab, A; Stein, P; Taha, T | 1 |
| Alvarenga, MJ; Santos, JC; Silva, AM; Vieira, AC | 1 |
| Fushimi, C; Hirai, H; Hoshino, E; Kamata, S; Kawakita, D; Masubuchi, T; Matsuki, T; Miura, K; Nagao, T; Ojiri, H; Saotome, T; Tada, Y; Takahashi, H | 1 |
| Barlev, A; Beebe-Dimmer, JL; Bylsma, LC; Flanders, SC; Fryzek, J; Gillezeau, C; Heath, E; Quek, RGW; Ruterbusch, JJ; Schultz, NM | 1 |
| Berry, DL; Crawford, ED; Dawson, NA; Donnelly, BJ; Ely, B; Higano, CS; Hussain, M; Kanaga Sundaram, S; Liu, G; Moinpour, CM; Prescott, S; Quinn, DI; Raghavan, D; Schellhammer, PF; Small, EJ; Tangen, CM; Thompson, IM; Vaishampayan, UN; Venner, PM; Vogelzang, NJ; Wilding, G | 1 |
| Chang, C; Fujimoto, N; Lee, SO; Li, L; Liang, L; Lin, TH; Niu, Y; Xu, D; Yeh, S; Yeh, SD | 1 |
| de Bono, JS; de Wit, R; Ebbinghaus, SW; Heath, KH; Hudes, GR; Li, X; Meulenbeld, HJ; Tagawa, ST; Whang, YE; Zandvliet, AS | 1 |
| Chang, C; Izumi, K; Lee, SO; Lin, TH; Lin, WJ; Yeh, S | 1 |
| Akhtar, A; Blackwell, K; Carey, LA; Danso, M; Doane, AS; Feigin, KN; Forero, A; Giri, DD; Gonzalez, JM; Gucalp, A; Hudis, CA; Ingle, JN; Isakoff, SJ; Liu, MC; Momen, LF; Moynahan, ME; Nabell, L; Patil, S; Rugo, H; Stearns, V; Tolaney, S; Traina, TA | 1 |
| Chung, J; Chung, JM; Ha, YS; Jung, YS; Kang, DI; Kim, IY; Kim, TH; Kim, WJ; Lee, DH; Lee, GT; Min, K; Moon, KH | 1 |
| Fujii, Y; Fukui, I; Masuda, H; Uehara, S; Yamamoto, S; Yano, A; Yonese, J; Yuasa, T | 1 |
| Agoulnik, AI; Agoulnik, IU; Coarfa, C; Frolov, A; Gandarillas, GA; Ittmann, MM; Li, R; Lopez, SM; Peterson, LE; Rajapakshe, K; Suarez, E; Weigel, NL; Zhang, M | 1 |
| Scholz, MC; Strum, SB | 1 |
| Baron, B; Chowdhury, S; Heidenreich, A; Holmstrom, S; Ivanescu, C; Klotz, L; Lin, P; Shore, ND; Siemens, DR; Villers, A; Wang, F | 1 |
| Bahary, JP; Balogh, AG; Dignam, JJ; Feng, FY; Grignon, DJ; Heney, NM; Kerlin, KJ; Lawton, CA; Lovett, RD; Lukka, HR; Major, PP; Patel, MP; Pisansky, TM; Pugh, SL; Rosenthal, SA; Sandler, HM; Sartor, O; Seiferheld, W; Shipley, WU; Souhami, L; Zeitzer, KL; Zietman, AL | 1 |
| Adam, TJ; Chen, SC; Curtis, KK; Gornet, MK; Pruthi, RK | 1 |
| Chen, N; Chen, XQ; Huang, R; Huang, Y; Li, X; Wei, Q; Xia, J; Yang, YR; Zeng, H; Zhang, P; Zhu, YC | 1 |
| Collette, L; de Reijke, TM; Goldschmidt, HM; Hetherington, J; Hoekstra, JW; Kariakine, OB; Kil, PJ; Studer, UE; Whelan, P; Wieggers, BJ | 1 |
| Lee, EC; Packman, K; Tenniswood, M; Zhan, P | 1 |
| Kirby, R | 2 |
| Anderson, J; Björk, T; Iversen, P; Kaisary, AV; Morris, T; Tammela, T; Tyrrell, CJ | 1 |
| Block, N; Jones, J; Kolvenbag, G; Patterson, AL; Sarosdy, M; Schellhammer, P; Sharifi, R; Soloway, M; Venner, P; Vogelzang, N | 1 |
| Iversen, P; Tveter, K; Varenhorst, E | 1 |
| Channer, K; Cockshott, ID; Denis, L; Newling, D; Soloway, M; Tyrrell, CJ | 1 |
| Anderson, JB; Baert, L; Blackledge, G; Chamberlain, M; Iversen, P; Kaisary, AV; Tammela, T; Tyrrell, CJ; Webster, A | 1 |
| Martorana, G | 1 |
| Tyrrell, CJ | 1 |
15 trial(s) available for bicalutamide and Metastase
| Article | Year |
|---|---|
Serial [
Topics: Aged; Androgen Antagonists; Anilides; Breast Neoplasms; Dihydrotestosterone; Female; Fluorine Radioisotopes; Follow-Up Studies; Humans; Neoplasm Metastasis; Nitriles; Positron-Emission Tomography; Prognosis; Prospective Studies; Radiopharmaceuticals; Receptors, Androgen; Tosyl Compounds | 2021 |
Validation of a 22-Gene Genomic Classifier in Patients With Recurrent Prostate Cancer: An Ancillary Study of the NRG/RTOG 9601 Randomized Clinical Trial.
Topics: Aged; Anilides; Follow-Up Studies; Genomics; Humans; Male; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Recurrence, Local; Nitriles; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Tosyl Compounds | 2021 |
A prospective phase II study of combined androgen blockade in patients with androgen receptor-positive metastatic or locally advanced unresectable salivary gland carcinoma.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Disease-Free Survival; Female; Humans; Leuprolide; Male; Middle Aged; Neoplasm Metastasis; Nitriles; Prospective Studies; Receptors, Androgen; Salivary Gland Neoplasms; Tosyl Compounds; Treatment Outcome | 2018 |
Intermittent versus continuous androgen deprivation in prostate cancer.
Topics: Aged; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Confidence Intervals; Drug Administration Schedule; Follow-Up Studies; Gonadotropin-Releasing Hormone; Goserelin; Humans; Male; Middle Aged; Neoplasm Metastasis; Nitriles; Penile Erection; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life; Survival Analysis; Tosyl Compounds | 2013 |
Differential androgen deprivation therapies with anti-androgens casodex/bicalutamide or MDV3100/Enzalutamide versus anti-androgen receptor ASC-J9(R) Lead to promotion versus suppression of prostate cancer metastasis.
Topics: Androgen Receptor Antagonists; Androgens; Anilides; Animals; Benzamides; Cell Line, Tumor; Curcumin; Down-Regulation; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Male; Matrix Metalloproteinase 9; Mice; Mice, Nude; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Transplantation; Neoplasms, Experimental; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms; Smad3 Protein; Tosyl Compounds; Transforming Growth Factor beta1; Transplantation, Heterologous; Xenograft Model Antitumor Assays | 2013 |
Tolerability, safety and pharmacokinetics of ridaforolimus in combination with bicalutamide in patients with asymptomatic, metastatic castration-resistant prostate cancer (CRPC).
Topics: Aged; Androgen Antagonists; Anilides; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug Interactions; Follow-Up Studies; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Nitriles; Orchiectomy; Prospective Studies; Prostatic Neoplasms; Sirolimus; TOR Serine-Threonine Kinases; Tosyl Compounds | 2013 |
Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents; Breast Neoplasms; Female; Hormones; Humans; Middle Aged; Neoplasm Metastasis; Nitriles; Receptors, Androgen; Receptors, Estrogen; Tosyl Compounds; Treatment Outcome | 2013 |
Impact of Enzalutamide Compared with Bicalutamide on Quality of Life in Men with Metastatic Castration-resistant Prostate Cancer: Additional Analyses from the TERRAIN Randomised Clinical Trial.
Topics: Anilides; Antineoplastic Agents; Benzamides; Cancer Pain; Carcinoma; Double-Blind Method; Humans; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Proportional Hazards Models; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Tosyl Compounds; Treatment Outcome | 2017 |
Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Combined Modality Therapy; Double-Blind Method; Follow-Up Studies; Gynecomastia; Humans; Incidence; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Nitriles; Prostatectomy; Prostatic Neoplasms; Radiotherapy; Survival Rate; Tosyl Compounds | 2017 |
Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents; Disease-Free Survival; Dose-Response Relationship, Drug; Half-Life; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Nitriles; Orchiectomy; Prostate-Specific Antigen; Prostatic Neoplasms; Tosyl Compounds; Treatment Outcome | 2006 |
Maximal androgen blockade for patients with metastatic prostate cancer: outcome of a controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy. Casodex Combination Study Group.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method; Flutamide; Follow-Up Studies; Goserelin; Humans; Leuprolide; Male; Middle Aged; Neoplasm Metastasis; Nitriles; Prostatic Neoplasms; Tosyl Compounds | 1996 |
Randomised study of Casodex 50 MG monotherapy vs orchidectomy in the treatment of metastatic prostate cancer. The Scandinavian Casodex Cooperative Group.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Dose-Response Relationship, Drug; Humans; Libido; Male; Middle Aged; Neoplasm Metastasis; Nitriles; Orchiectomy; Prostatic Neoplasms; Survival Rate; Tosyl Compounds | 1996 |
Casodex 10-200 mg daily, used as monotherapy for the treatment of patients with advanced prostate cancer. An overview of the efficacy, tolerability and pharmacokinetics from three phase II dose-ranging studies. Casodex Study Group.
Topics: Acid Phosphatase; Androgen Antagonists; Anilides; Antineoplastic Agents; Dose-Response Relationship, Drug; Estradiol; Follicle Stimulating Hormone; Humans; Liver Function Tests; Luteinizing Hormone; Male; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Staging; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Testosterone; Tosyl Compounds | 1998 |
A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Bone Neoplasms; Castration; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Nitriles; Probability; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life; Survival Rate; Tosyl Compounds; Treatment Outcome | 1998 |
Casodex: a pure non-steroidal anti-androgen used as monotherapy in advanced prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents; Drug Evaluation; Humans; Male; Middle Aged; Neoplasm Metastasis; Nitriles; Prostatic Neoplasms; Tosyl Compounds; Treatment Outcome | 1992 |
16 other study(ies) available for bicalutamide and Metastase
| Article | Year |
|---|---|
Aromatase-induced endogenous estrogen promotes tumour metastasis through estrogen receptor-α/matrix metalloproteinase 12 axis activation in castration-resistant prostate cancer.
Topics: Aged; Anilides; Animals; Aromatase; Cell Line, Tumor; Epithelial-Mesenchymal Transition; Estrogen Receptor alpha; Estrogens; Gene Expression Regulation, Neoplastic; Humans; Hyaluronan Receptors; Letrozole; Male; Matrix Metalloproteinase 12; Mice; Middle Aged; Neoplasm Metastasis; Nitriles; PC-3 Cells; Prostatic Neoplasms, Castration-Resistant; Tosyl Compounds; Up-Regulation | 2019 |
Anti-androgen for myoepithelial tumor: a potent therapy yet a potential misleader.
Topics: Aged; Androgen Antagonists; Anilides; Humans; Lung Neoplasms; Male; Myoepithelioma; Neoplasm Metastasis; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Tosyl Compounds | 2022 |
Paraneoplastic jaundice and prostate cancer.
Topics: Aged; Anilides; Humans; Jaundice; Male; Neoplasm Metastasis; Nitriles; Paraneoplastic Syndromes; Prostatic Neoplasms; Tosyl Compounds; Treatment Outcome | 2017 |
Patterns of Bicalutamide Use in Prostate Cancer Treatment: A U.S. Real-World Analysis Using the SEER-Medicare Database.
Topics: Aged; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Cohort Studies; Databases, Factual; Drug Therapy, Combination; Gonadotropin-Releasing Hormone; Humans; Male; Medicare; Neoplasm Metastasis; Nitriles; Practice Patterns, Physicians'; Prostatic Neoplasms; SEER Program; Tosyl Compounds; United States | 2018 |
Anti-androgen receptor ASC-J9 versus anti-androgens MDV3100 (Enzalutamide) or Casodex (Bicalutamide) leads to opposite effects on prostate cancer metastasis via differential modulation of macrophage infiltration and STAT3-CCL2 signaling.
Topics: Androgen Antagonists; Androgen Receptor Antagonists; Anilides; Animals; Antineoplastic Agents; Benzamides; Cell Movement; Chemokine CCL3; Coculture Techniques; Curcumin; Humans; Macrophages; Male; Mice; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Signal Transduction; STAT3 Transcription Factor; Tosyl Compounds | 2013 |
Prostate cancer bone metastases acquire resistance to androgen deprivation via WNT5A-mediated BMP-6 induction.
Topics: Adult; Androgen Antagonists; Anilides; Bone Morphogenetic Protein 6; Bone Neoplasms; Cell Communication; Cell Growth Processes; Cell Line, Tumor; Humans; Male; Middle Aged; Neoplasm Metastasis; Nitriles; Orchiectomy; Prostatic Neoplasms, Castration-Resistant; Proto-Oncogene Proteins; Receptors, Androgen; Retrospective Studies; Stromal Cells; Tosyl Compounds; Wnt Proteins; Wnt-5a Protein | 2014 |
Prior administration of a non-steroidal anti-androgen failed to prevent the flare-up caused by a luteinizing hormone-releasing hormone agonist in a patient with metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Anilides; Anti-Inflammatory Agents, Non-Steroidal; Disease Progression; Gonadotropin-Releasing Hormone; Humans; Male; Neoplasm Metastasis; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Tosyl Compounds | 2015 |
Nuclear Receptor Corepressor 1 Expression and Output Declines with Prostate Cancer Progression.
Topics: Androgen Antagonists; Androgens; Anilides; Animals; Cell Line, Tumor; Disease Models, Animal; Disease Progression; Gene Expression; Gene Knockdown Techniques; Gene Silencing; Humans; Male; Mice; Mice, Transgenic; Neoplasm Metastasis; Nitriles; Nuclear Receptor Co-Repressor 1; Prostatic Neoplasms; RNA Interference; Tosyl Compounds; Transcriptome | 2016 |
Adverse Health Effects of Intermittent vs Continuous Androgen Deprivation Therapy for Metastatic Prostate Cancer: Relating 33 Years of Patient Clinical Care.
Topics: Androgen Antagonists; Androgens; Anilides; Drug-Related Side Effects and Adverse Reactions; Flutamide; Gonadotropin-Releasing Hormone; Humans; Leuprolide; Libido; Male; Medicare; Neoplasm Metastasis; Nitriles; Penis; Prostatic Neoplasms; Tosyl Compounds; United States | 2016 |
Anaemia following initiation of androgen deprivation therapy for metastatic prostate cancer: a retrospective chart review.
Topics: Aged; Androgen Antagonists; Anemia; Anilides; Antineoplastic Agents, Hormonal; Combined Modality Therapy; Goserelin; Hemoglobins; Humans; Leuprolide; Linear Models; Male; Neoplasm Metastasis; Nitriles; Prostatic Neoplasms; Retrospective Studies; Tosyl Compounds | 2008 |
Efficacy of maximal androgen blockade versus castration alone in the treatment of advanced prostate cancer: a retrospective clinical experience from a Chinese medical centre.
Topics: Aged; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; China; Combined Modality Therapy; Disease-Free Survival; Flutamide; Gonadotropin-Releasing Hormone; Humans; Kaplan-Meier Estimate; Male; Multivariate Analysis; Neoplasm Metastasis; Nitriles; Orchiectomy; Prostatic Neoplasms; Retrospective Studies; Tosyl Compounds | 2010 |
Tissue polypeptide-specific antigen (TPS) determinations before and during intermittent maximal androgen blockade in patients with metastatic prostatic carcinoma.
Topics: Androgen Antagonists; Anilides; Follow-Up Studies; Humans; Male; Neoplasm Metastasis; Nitriles; Peptides; Prognosis; Prostatic Neoplasms; Tosyl Compounds | 2003 |
Induction of invasive phenotype by Casodex in hormone-sensitive prostate cancer cells.
Topics: Anilides; Antineoplastic Agents; Cell Cycle; Cell Death; Culture Media, Serum-Free; DNA Fragmentation; Flow Cytometry; Humans; Kinetics; Male; Neoplasm Invasiveness; Neoplasm Metastasis; Nitriles; Phenotype; Prostatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; Time Factors; Tosyl Compounds; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 2002 |
Case study: management of advanced prostate cancer with soft tissue metastases.
Topics: Adenocarcinoma; Anilides; Disease Progression; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Nitriles; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Quality of Life; Risk; Soft Tissue Neoplasms; Time Factors; Tomography, X-Ray Computed; Tosyl Compounds; Treatment Outcome | 2005 |
Case study: management of lymph node-positive disease detected at radical prostatectomy.
Topics: Adenocarcinoma; Aged; Anilides; Biopsy; Disease Progression; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Neoplasm Metastasis; Nitriles; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Prunus; Quality of Life; Tosyl Compounds; Vitamin B Complex | 2005 |
[Adjuvant hormone therapy in prostatic cancer: after treatment with curative intent. The viewpoint of the urologist].
Topics: Adult; Aged; Androgen Antagonists; Anilides; Antineoplastic Agents; Chemotherapy, Adjuvant; Clinical Trials as Topic; Follow-Up Studies; Humans; Male; Neoplasm Metastasis; Neoplasm Recurrence, Local; Nitriles; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Time Factors; Tosyl Compounds | 2002 |